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Abstract—One of the major problems related to cancer treat-
ment is its recurrence. Without knowing in advance how likely 
the cancer will relapse, clinical practice usually recommends ad-
juvant treatments that have strong side effects. A way to optimize 
treatments is to predict the recurrence probability by analyzing 
a set of bio-markers. The NeoMark European project has identi-
fied a set of preliminary bio-markers for the case of oral cancer 
by collecting a large series of data from genomic, imaging, and 
clinical evidence. This heterogeneous set of data needs a proper 
representation in order to be stored, computed, and communi-
cated efficiently. Ontologies are often considered the proper mean 
to integrate biomedical data, for their high level of formality and 
for the need of interoperable, universally accepted models. This 
paper presents the NeoMark system and how an ontology has been 
designed to integrate all its heterogeneous data. The system has 
been validated in a pilot in which data will populate the ontology 
and will be made public for further research. 
Index Terms—Biomedical image processing, cancer, computer 
aided diagnosis, genetic expression. 
I. INTRODUCTION 
C ANCER is the second cause of death in western coun-tries. Although current treatments can be effective, the 
main problem of cancer is its recurrence either locally or by dis-
tant metastases, which are difficult to predict and prevent. The 
oral squamous cell carcinoma (OSCC), focus of this research, 
accounts for the 5% of all cancers, and has a rate of 25-50% 
of recurrence in Ave years, 90% of which within two years 
from surgery [1]. In order to avoid relapses, adjuvant chemo- or 
radio-therapy treatments are usually administered to all patients 
during follow-up, even in absence of disease signs. These treat-
ments are heavy and have strong side effects that may harm also 
patients who are in fact already completely recovered. Know-
ing in advance which patients have the higher risk of disease 
recurrence, would help to initiate adjuvant treatments only in a 
limited, high-risk subgroup. In addition, the early identification 
of a neoplastic recurrence during follow-up would allow starting 
an appropriate treatment in time. 
The most classical method to predict OSCC recurrence is 
the tumor, node, and metastasis (TNM) staging, which is based 
mainly on the dimensional characteristics of the tumor and on 
the presence, number, and site of neck nodes metastasis. Un-
fortunately, its inadequacy is today recognized because of the 
uncertain behavior of squamous cancer, which can be some-
times very aggressive and others can metastasize slowly after 
surgery [2]. This uncertainty in progression has led researchers 
to seek a larger number of markers. Many clinical, histopatho-
logical, radiological, and genetic factors were studied, but none 
of the different groups taken, distinctly provides clinically appli-
cable markers of tumor aggressiveness [3]. Given the multilevel 
nature of cancer (genes, cells, tissues, and organs), integration 
of the different groups of data are required. Whereas differ-
ent reports are present in the literature on data integration and 
creation of standardized prognostic algorithms for bladder and 
breast cancer, nothing is available for head and neck cancer. To 
cover this lack, the NeoMark project was created. 
NeoMark [4] is an European cofunded research project, which 
aimed at identifying the optimal set of patient-speciflc and 
disease-specific bio-markers with a high-predictive power for 
the case of OSCC cancer. 
The NeoMark strategy is designed to be integrated into nor-
mal staging and follow-up protocols. Patients are assessed be-
fore treatment and, at the time of remission, a wide range of 
data is collected including clinical observations, radiologic, and 
genomic data. A set of relevant markers expressed only in pres-
ence of the disease is then selected and relapse probability is 
estimated. If the same set of bio-markers appears during postre-
mission follow-up, it would show a high probability of relapse, 
advising early intervention. 
This strategy is supported by an Information and Communica-
tions Technology (ICT)-based system which allows physicians 
to 
1) administer patients; 
2) upload clinical data including histological information, 
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Fig. 1. Architecture of the NeoMark system. 
3) analyze jointly multiple images from MR/CT scans; 
4) analyze gene expressions by means of microarrays and a 
mobile PCR system; 
5) receive indicators of the probability of relapse for support-
ing the clinical decision during the follow up; 
6) download anonymized data for further research and 
statistics. 
The following sections describe the details of the NeoMark 
system, how an ontology for integrating all the data collected 
in the system has been designed, some results of the pilot we 
ran to prove its effectiveness and the conclusions and some 
suggestions for future developments. 
II. METHODS 
A. NeoMark System 
The NeoMark system was designed as a flexible, user-
friendly, service-oriented system. The system comprises the 
following modules, as depicted in Fig. 1. 
1) Integrated Health Record Repository (IHRR): It is a cen-
tral database that collects all the patients data in a central entity 
anonymously (only a unique identifier is kept for each patient). 
A web-based data entry provides all the functionalities to add, 
manage, and review patients data. In order to link patients clin-
ical data with their sensitive information, a stand-alone applica-
tion has been developed to manage this link with the database 
located in the hospital network. 
Additionally to the web data entry, the IHRR provides a re-
mote interface to other three dedicated applications that upload 
patients data, and to a data analysis module that is in charge 
of creating patient-specific models for estimating cancer recur-
rence. These external tools are detailed in the following sections. 
2) Image processing tool (IPT): It is used to extract mean-
ingful numeric features of tumors and suspicious lymph nodes 
from CT, CT with contrast, MR Tl TSE, and MR T2 TSE head 
and neck images. Prerequisite for the feature extraction is an 
image fusion of the CT and MRI scans provided by the means 
of image registration as well as the segmentation of the region 
of interests (tumors and suspicious lymph nodes). 
For image registration, the IPT deploys a fully automated 
mutual information-based rigid registration method [5]. It is ro-
bust against truncation and imaging artifacts as they are typically 
present in clinically acquired medical images. In order to satisfy 
the rigidity assumption, not only in the head but also in the de-
formable neck, the patients had been placed in the same position 
during image acquisition using the different imaging modalities. 
In a second step, the operator selects relevant lymph nodes by 
clicking into the approximate center. Starting from there, a ra-
dial ray-based segmentation technique is used to segment the 
lymph nodes automatically [6]. Due to the unpredictability of 
the shape, appearance, and surrounding tissue of the tumor, an 
interactive approach is used for tumor segmentation [7]. 
In the third phase, from the segmentation process some ge-
ometric and texture-based features are automatically extracted, 
including volume, 3-D axes, contrast take-up rate and water con-
tent. Finally, the location and the amount of infiltration of the 
surrounding tissue are estimated manually. All these features, 
including images, are then uploaded to the IHRR. 
3) Genomic data filtering tool: Blood samples and tumor 
samples are analyzed with a standard microarray scanner which 
produces a feature extraction (FE) file with the extracted values. 
A FE file is a tab delimited text file, which contains Log2-ratio 
values as well as raw intensity data, background information, 
metadata on the experiment and on the scanning settings and 
annotations to identify genes. In order to reduce the amount of 
collected data, we only consider as relevant information the fea-
ture name, probe name, gene name, systematic name, descrip-
tion, and Log2-ratio. The Genomic data Altering tool discards 
irrelevant data and low quality or duplicate features producing 
as output a cleaner and lighter file containing only relevant fields 
for the analysis. These new files are eventually assigned to the 
specific patient and sample and uploaded to the common repos-
itory, while the original copy of the FE file is kept in the local 
hospital repository. 
4) qRT-PCR tool: Within the project, a portable, real time, 
low-cost quantitative real time polymerase chain reaction (qRT-
PCR) tool has been developed. Its objective is to serve as a 
lab-on-a-chip alternative to microarrays for examining patient's 
RNA extracted from lymphocytes. The tool analyzes a set of 
predefined genes (up to 20) and reports their expression value 
in relation with a housekeeping gene. It is composed of a core 
silicon chip containing heaters and thermal sensors, a cooling 
fan, and an optical system that detects the fluorescence intensity 
of the monitored reaction. The practitioner, after preparing the 
chips with genetic material, operates a SW tool that controls the 
device, clears and Alters data, and sends it to the IHRR. 
5) Data analysis: It is a module in charge of creating the 
patient-specific estimation model of cancer recurrence. Its role 
is twofold. As soon as the patient reaches remission, an initial 
profile of the patient is created by analyzing clinical, imaging, 
and gene expression data. The objective of this first step is to 
stratify patients into two classes: remittents and nonremittents. 
A feature selection is executed for the purpose: outliers are 
detected, missing values are handled, and redundant features 
are discarded. The adopted feature selection mechanisms are 
significance analysis of microarrays (SAM) [8] and correlation-
based feature subset selection (CFS) [9]. The reduced set of 
features is then fed to a set of classification algorithms which 
have been trained carefully. 
The second role of the module is to model the evolution 
of the disease during the whole follow-up period in order to 
early identify potential relapses. The following classifiers are 
employed: bayesian networks (BN), artificial neural networks 
(ANN), support vector machines (SVM), decision trees (DT), 
and random forests (RF). In order to avoid overfitting, a tenfold 
cross validation is also performed. 
B. NeoMark Ontology 
The IHRR uses a standard relational database for storing and 
retrieving data. Nevertheless, one of the objective of the project 
was to provide the data in a semantic structure by means of an 
OWL ontology. For this reason, a component of the IHRR is 
dedicated to generating RDF instances of the data according to 
a specific model: the NeoMark ontology [10]. 
The objectives of the ontology are as follows: 
1) to represent the domain of the project and documenting it; 
2) to link the NeoMark data to other domains and en-
sure interoperability by including established existing 
ontologies; 
3) to share the data created within the pilot with a formal 
semantic. 
The NeoMark ontology was built starting from the existing 
database included in the IHRR. We developed a tool, based 
on the work shown in [11], that translates tables, columns, 
and foreign keys of a standard relational database into classes, 
data properties, and object properties. We run the tool on the 
NeoMark database and we obtained a first approximation of 
the ontology, which comprised all the concepts and all the rela-
tionships that were in use within the system, but represented in 
a poorly structured way and with almost no explicit semantic. 
Since the NeoMark domain integrates several types of hetero-
geneous data, we decided to base it on an upper ontology. The 
adoption of the principles of the open biological and biomedical 
ontologies (OBO) foundry [12] was the natural choice given 
the domain of our application. We imported the basic formal 
ontology (BFO) and the relation ontology (RO) and reordered 
the concepts of the automatically generated ontology on top of 
them. The result was a much more formal ontology, but was 
still lacking interoperability with other existing initiatives. For 
importing existing ontologies, we adopted the recommended 
approach of the OBO foundry: the minimum information to 
reference an external ontology term (MIREOT) [13]. More con-
cretely, we used the OntoFox tool [14], which implements and 
expands the MIREOT approach. 
We analyzed the ontologies currently deployed in the OBO 
foundry to find reusable concepts. Eventually, the following 
terms were imported: 
1) from the ontology of biomedical investigations (OBI), 
the terms "patient role," "lymph node," "gene list," and 
"disease"; 
2) from the ontology for general medical science (OGMS), 
the "clinical finding," "prognosis," and "treatment" 
taxonomies; 
3) from the human disease ontology (HDO), the malignant 
neoplasm of lip, oral cavity, and pharynx taxonomy. 
The integration of these ontologies was simple because both 
OBI and OGMS are based on the BFO ontology, while HDO 
was included by making equivalent the term "disease" between 
HDO and OBI. 
The existing ontologies were imported including all interme-
diate terms between classes and computing all axioms recur-
sively. A further process was setup to prune irrelevant terms 
from the current model and reorganize the terms that were not 
included in the imported ontologies, but that were still necessary 
to represent the NeoMark domain. Following, we show the root 
class of the added taxonomies and their direct superclasses in 
the merged ontologies: 
1) ''tumor finding'' taxonomy (subclass 
of ""clinical finding''); 
2) ""lymph node finding'' taxonomy 
(subclass of " "clinical finding''); 
3) ""patient quality of life evaluation'' 
taxonomy (subclass of ""physical 
examination finding''); 
4) ""patient risk factor'' taxonomy 
(subclass of ""clinical finding''); 
5) ""microarray data'' (subclass of 
1
"laboratory finding''); 
6) ""qPCR data'' (subclass of ""laborato-
ry finding''); 
7) " "gene list'' (subclass of ""data set''); 
8) ""gene ontology term'' (subclass of 
""data set'') ; 
9) ""recurrence prediction'' taxonomy 
(subclass of ""prognosis''); 
10) ""surgical treatment'' taxonomy 
(subclass of ""treatment''); 
11) ""nonsurgical treatment'' taxonomy 
( s u b c l a s s of " " t r e a t m e n t ' ' ) . 
In addition to specific classes, some ad hoc relationships had 
to be added to the model. All relationships were derived from 
the relation ontology. The relations, described using Manchester 
OWL syntax, are shown as follows: 
1) ""patient role'' contains only ""lymph 
node,'' 
2) ""patient role'' contains exactly 1 
1
"malignant neoplasm of lip, oral 
cavity and pharynx,'' 
3) ""malignant neoplasm of lip, oral 
cavity and pharinx'' contained_in 
exactly 1 ""patient role,'' 
4) ""lymph node'' contained_in exactly 1 
1
"patient role,' ' 
5) ""lymph node finding''is_about exactly 
1 ""lymph node,'' 
6) ""tumor finding'' is_about exactly 1 
1
"malignant neoplasm of lip, oral 
cavity, and pharynx,'' 
7) ""clinical finding'' is_about exactly 
1 ""patient role,'' 
8) ""prognosis'' is_about exactly 1 
1
"patient role,'' 
9) ""patient role'' participates_in min 1 
1
"treatment,'' 
10) ""treatment'' has_participant exactly 
1 ""patient role,'' 
11) ""treatment'' precedes only ""post 
treatment,'' 
12) " "post treatment' ' precedecLby some 
1
"treatment,'' 
13) ""surgical procedure'' precedes some 
'"surgical reconstruction,'' 
14)""surgical reconstruction'' preceded_by 
some ""surgical procedure,'' 
15) ""gene ontology term list'' has.part 
only ""gene ontology term," 
16) ""gene ontology term'' part_of only 
'"gene ontology term list,'' 
17)""microarray input gene list'' is.about 
exactly 1 ""patient role,'' 
18)""microarray output gene list'' is_about 
exactly 1 ""patient role,'' 
19)""gene ontology term'' contains exactly 
1 ""gene ontology term gene list,'' 
20) ""gene ontology term gene list'' 
contained_in exactly 1 ""gene ontology 
term''. 
III. R E S U L T S 
The NeoMark system was validated in a pilot which in-
volved 86 OSCC patients treated with surgery with more than 
12 months of follow-ups in three clinical centers in Italy and 
Spain. 
From the technical perspective, the maturity, the usability, 
and the perceived usefulness were validated. The maturity of the 
system was evaluated by setting up an issue tracker (GForge) 
that was used by the clinicians during the study. In total, 58 
technical problems were reported and 33 new features were 
requested. At the end of the study, no reported errors were still 
open and only a minority of requests for changes, on which no 
common agreement was reached, were still open. 
For validating usability and usefulness, a specific question-
naire was sent to 24 respondents who were using the system 
in the clinical centers (radiologists, biologists, maxillofacial 
surgeons, and laboratory technicians). The questionnaire was 
designed with cross-check questions expressed in positive and 
negative answers. The aggregated results show positive feed-
back with regards to easiness of use and user friendliness (55% 
of respondents were positive) and usefulness (67.2% of respon-
dents were positive). The validation of the developed tools, espe-
cially the image processing tool and the qRT-PCR tool demon-
strated the possibility to improve the decision-making process 
of physicians by enhancing and speeding up some critical diag-
nostic exams and by integrating data through an accurate and 
usable software platform. 
From the clinical perspective, risk prediction was validated, 
both as risk stratification of patients at diagnosis (baseline) and 
recurrence risk evaluation during follow-up. Clinicians vali-
dated the risk prediction results via vis-á-vis the real evolution 
of the disease in subsets of patients, and verified in parallel the 
factors and genomic markers identified by NeoMark against the 
most recent findings from the scientific research. 
The classification performances per type of input data can be 
summarized as follows [15]. 
1) For the clinical data, accuracy is around 78%. 
2) For the imaging-only data, accuracy is around 88%. 
3) For the tissue genomic data, accuracy is around 88%. 
4) The best performing algorithm for the cases aforemen-
tioned is the CFS combined with SVM classifier. 
5) For the blood genomic, the most adequate classification 
scheme was ANN without any previous feature selection 
with an accuracy of approximately 96%. 
When combining these classification schemes into a consen-
sus classifier, accuracy reaches approximately 92% with 83% 
sensitivity and 100% of specificity. 
The NeoMark data analysis also allowed us to select a better 
set of genes with higher prediction power than already identified 
in the literature, particularly. 
1) From an initial set of 45015 genes, our best selection 
includes a mix of 37 genes. The best results are achieved 
when the genes identified from data analysis are combined 
with the ones in the literature. An optimized selection 
includes 9 genes from the literature and 11 found within 
NeoMark. 
2) A minimized set of genes with an acceptable accuracy in-
cludes 9 genes, 5 of which were identified by the NeoMark 
system. 
Regarding the evaluation of the NeoMark ontology, it was val-
idated in different steps throughout its development. The eval-
uation of an ontology is typically carried out from two points 
of view: the technical evaluation is performed by developers 
and the users evaluation is done by experts of the domain [16]. 
In NeoMark, the technical evaluation for consistency was done 
with standard reasoners included in Protege. Users' evaluation 
was performed in this way: while the terms were added or pruned 
from the existing taxonomies, five experts of the project, doc-
tors, and biologists, helped us to assess the completeness and 
coherence of the model. These evaluations allowed us to cor-
rect inconsistencies, predominantly during the conceptualiza-
tion phase and avoided errors to propagate. The current version 
of the ontology is publicly available at the National Center for 
Biomedical Ontology BioPortal1. 
We are currently completing the integration of the IHRR data 
with the NeoMark ontology and performing the last adaptations 
to guarantee that all the data of the pilot are correctly represented 
in the model. As soon as the the ontology export feature of the 
IHRR is finalized, all the data of the pilot will be made available 
as an OWL ontology to be downloaded at the NeoMark website2. 
We are also planning to integrate a SPARQL engine into the web 
interface of our system to make it easier for researchers to query 
for relevant data. 
'http://purl.bioontology.org/ontology/NeoMark 
2http://www.neomark.eu 
IV. CONCLUSION AND FUTURE WORK 
This paper has shown a novel ICT-enabled cancer recurrence 
prediction method, a system that implements the method for the 
OSCC case and an ontology that models all the data managed by 
the system. The clinical validation has shown that NeoMark can 
enable the identification of integrated and reduced sets of mark-
ers. Almost all the clinical and imaging identified markers are 
coherent with the most recent findings of research in this field, 
while additional factors, especially related to tissue and blood 
genomic, were identified by the NeoMark. If NeoMark-specific 
genes are combined with most performing genes extracted from 
the literature, the accuracy of the prediction tool increases 
considerably. 
The validation of the system, although generally positive, 
showed that some improvements are still necessary. 
Regarding technical aspects, some fixes on the user interfaces 
are needed and the response time of the system must be reduced 
considerably. From the clinical point of view, risk prediction 
should be further assessed through a longer and wider clinical 
study, in order to assess how valuable it can be for decision 
making. At the present stage, the indications of NeoMark risk 
prediction can be helpful in triggering additional attention to 
aspects which may be not visible, especially in radiology and 
in follow-up visits. Currently, the system works as a sentinel, 
but it does not provide insights about the possible mechanisms 
through which the recurrence occurs. Its use, though, can be ex-
tended as an instrument for further research, e.g., combined with 
retrospective studies on tissue samples available in tumor banks. 
Regarding the ontology, as it was based on the OBO standard 
upper ontologies, its future revisions could be easily extended 
with new OBO ontologies as substitutes of manual added terms 
and relations. 
ACKNOWLEDGMENT 
The authors would like to thank the whole NeoMark Con-
sortium for their valuable contribution for the realization of this 
work. 
REFERENCES 
[1] P. Boyle and B. Levin, "World cancer report 2008," International 
Agency for Research on Cancer, Lyon, France, Rep., 2008. Available: 
http://www.iarc.fr/en/publications/pdfs-online/wcr/2008/wcr_2008.pdf 
[2] J. A. Woolgar, "Histopathological prognosticators in oral and oropharyn-
geal squamous cell carcinoma," Oral Oncol., vol. 42, no. 3, pp. 229-239, 
Mar. 2006. 
[3] R. d. e. C. Lindenblatt, G. L. Martinez, L. E. Silva, P. S. Faria, 
D. R. Camisasca, and S. d. e. Q. Lourenco, "Oral squamous cell carci-
noma grading systems—Analysis of the best survival predictor," J. Oral 
Pathol. Med., vol. 41, no. 1, pp. 34-39, Jan. 2012. 
[4] M. Picone, S. Steger, K. Exarchos, M. Fazio, Y. Goletsis, D. I. Fotiadis, 
E. Martinelli, and D. Ardig, "Enabling heterogeneous data integration 
and biomedical event prediction through ict: The test case of cancer 
reoccurrence," in Software Tools and Algorithms for Biological Sys-
tems (Advances in Experimental Medicine and Biology Series 696), 
H. R. R. Arabnia and Q.-N. Tran, Eds. New York: Springer-Verlag, 
2011, pp. 367-375. 
[5] S. Steger and M. Keil, "Automated initialization and region of interest 
detection for successful head registration of truncated ct/mr head & neck 
images," in Proc.lOth IEEE Int. Conf. Inf. Technol. Appl. Biomed., 2010, 
pp. 1-5. 
[6] S. Steger and G. Sakas, "Image gradient based shape prior for the seg-
mentation of not that spherical structures," in Proc.9th IEEE Int. Symp. 
Biomed. Imag., May 2012, pp. 1252-1255. 
[7] S. Steger and G. Sakas, "FIST: Fast interactive segmentation of tumors," 
in Abdominal Imaging Computational and Clinical Applications (Lec-
ture Notes in Computer Science Series 7029), H. Yoshida, G. Sakas, 
and M. Linguraru, Eds. Berlin/Heidelberg, Germany: Springer-Verlag, 
2012, pp. 125-132. 
[8] V. Tusher, R. Tibshirani, and G. Chu, "Significance analysis of microarrays 
applied to the ionizing radiation response," Proc. Natl. Acad. Sci. USA, 
vol. 98, pp. 5116-5121, Apr. 2001. 
[9] M. A. Hall, "Correlation-based feature selection for discrete and numeric 
class machine learning," in Proc. 17th Int. Conf. Mach. Learn. San Fran-
cisco, CA: Morgan Kaufmann, 2000, pp. 359-366 
[10] I. Martin, M. Ortega, D. Salvi, Á. Esteban, and M. Picone. (2011). "Neo-
mark internal report 4.1, ontologies and semantic integration," Tech. Rep. 
[Online]. Available: http://lnx.neomark.eu/portal/images/articles/pdf/ 
public_deliverables/ir 4. l_ontologies_semantic_integration.pdf 
[11] Z. Xu, S. Zhang, and Y. Dong, "Mapping between relational database 
schema and owl ontology for deep annotation," in Proc. IEEE Web 
Intell.ACM Int. Conf, Dec. 2006, pp. 548-552. 
[12] B. Smith, M. Ashburner, C. Rosse, J. Bard, W. Bug, W. Ceusters, 
L. J. Goldberg, K. Eilbeck, A. Ireland, C. J. Mungall, the OBI Con-
sortium, N. Leontis, P. Rocca-Serra, A. Ruttenberg, S.-A. Sansone, 
R. H. Scheuermann, N. Shah, P. L. Whetzel, and S. Lewis, "The obo 
foundry: Coordinated evolution of ontologies to support biomedical data 
integration," Nature Biotechnol, vol. 25, no. 11, Nov. 2007. 
[13] M. Courtot, F Gibson, A. L. Lister, J. Maione, D. Schober, 
R. R. Brinkman, and A. Ruttenberg, "Mireot: The minimum informa-
tion to reference an external ontology term," J. Appl. Ontol, vol. 6, 
no. 1, pp. 23-33, 2011. DOI: 10.3233/AO-2011-0087. [Online]. Avail-
able: http://iospress.metapress.com/content/h54m2237310vl3xl/ 
[14] Z. Xiang, M. Courtot, R. R. Brinkman, A. Ruttenberg, and Y He, "Onto-
fox: Web-based support for ontology reuse," BMC Res. Notes, vol. 3, 
2010. Available: http://www.biomedcentral.eom/1756-0500/3/175 
[15] K. Exarchos, Y Goletsis, T. Poli, and D. Fotiadis, "Gene expression pro-
filing towards the prediction of oral cancer reoccurrence," in Proc. 33rd 
Annu. Int. Conf. IEEE Eng. Med. Biol. Soc, Aug. 2011, pp. 8307-8310. 
Available: http://ieeexplore.ieee.org/xpl/articleDetails.jsp7reload = true& 
arnumber=6092048&contentType=Conference+ Publications 
[16] A. Gómez-Pérez, M. Fernández-López, and Óscar Corcho, Ontologi-
cal Engineering with examples from the areas of Knowledge Manage-
ment, e-Commerce and the Semantic Web. London, U.K.: Springer-
Verlag, 2004, 420 pp. Available: http://www.springer.com/computer/ 
information+systems+and+applications/book/978-1-85233-551-9 
